Down syndrome (DS) is the major cause of intellectual disability in humans and it is estimated there are over 300,000 individuals with this genetic disorder in the United States. Virtually all DS individuals have sufficient neuropathology for a diagnosis of AD in their 40th year. However, dementia may not develop until up to a decade later and some people remain cognitively intact. Thus, we seek to follow a group of adults ranging in age from 20-40 years over a 5 year period of time to identify age and dementia-associated changes in cognition and in particular focus on frontal lobe function.
Our aims are four-fold.
Aim 1 will cognitively characterize a cohort of adults with DS and follow individuals for a period of 5 years.
Aim 2 will use magnetic resonance imaging to measure white matter integrity on an annual basis in longitudinally followed people.
Aim 3 will assay plasma drawn annually from the cohort and measure signaling protein changes to identify biomarkers of AD development and that are also correlated with cognition.
Aim 4 will study archived and new autopsy brain samples from DS adults to identify molecular pathways that change prior and during AD development. The outcomes of the proposed studies will contribute to the development of noninvasive biomarkers that will assist in early AD diagnosis in DS and monitor disease progression. Further, novel biomarkers that are mechanistically related to aging, AD neuropathology and dementia will also provide outcomes for the design of future therapeutic clinical trials to treat or prevent dementia in DS.
The proposed study will identify new ways in which to detect Alzheimer disease (AD) in adults with Down syndrome (DS) by monitoring changes in cognitive function, measuring brain changes by magnetic resonance imaging and profiling patterns of proteins in the plasma. In parallel, autopsy studies of brain samples will help us to understand how noninvasive cognitive, imaging and blood measures reflect the development of AD in DS. Treatments for AD in DS will be more effective if the disease is detected early and identifying biomarkers will greatly facilitate the development of therapeutics.
|Perluigi, Marzia; Pupo, Gilda; Tramutola, Antonella et al. (2014) Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta 1842:1144-53|
|Di Domenico, Fabio; Pupo, Gilda; Tramutola, Antonella et al. (2014) Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med 71:270-80|
|Powell, David; Caban-Holt, Allison; Jicha, Gregory et al. (2014) Frontal white matter integrity in adults with Down syndrome with and without dementia. Neurobiol Aging 35:1562-9|
|Butterfield, D Allan; Di Domenico, Fabio; Swomley, Aaron M et al. (2014) Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J 463:177-89|
|Martin, Sarah B; Dowling, Amy L S; Lianekhammy, Joann et al. (2014) Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease. J Alzheimers Dis 42:767-75|
|Jicha, Gregory A; Rentz, Dorene M (2013) Cognitive and brain reserve and the diagnosis and treatment of preclinical Alzheimer disease. Neurology 80:1180-1|
|Mathews, Melissa; Abner, Erin; Caban-Holt, Allison et al. (2013) CERAD practice effects and attrition bias in a dementia prevention trial. Int Psychogeriatr 25:1115-23|
|Di Domenico, Fabio; Coccia, Raffaella; Cocciolo, Annalisa et al. (2013) Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta 1832:1249-59|
|Cenini, Giovanna; Dowling, Amy L S; Beckett, Tina L et al. (2012) Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta 1822:130-8|
|Holler, Christopher J; Webb, Robin L; Laux, Ashley L et al. (2012) BACE2 expression increases in human neurodegenerative disease. Am J Pathol 180:337-50|
Showing the most recent 10 out of 12 publications